Media headlines about CTI BioPharma (NASDAQ:CTIC) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CTI BioPharma earned a news impact score of 0.17 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3522262150755 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Shares of CTI BioPharma traded down $0.01, hitting $5.09, during trading hours on Monday, MarketBeat.com reports. 2,916 shares of the company’s stock were exchanged, compared to its average volume of 259,777. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.32 and a quick ratio of 5.30. The company has a market cap of $295.68 million, a price-to-earnings ratio of -4.10 and a beta of 0.15. CTI BioPharma has a fifty-two week low of $2.45 and a fifty-two week high of $5.19.

CTI BioPharma (NASDAQ:CTIC) last announced its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. The business had revenue of $10.48 million during the quarter, compared to the consensus estimate of $10.30 million. CTI BioPharma had a negative return on equity of 63.27% and a negative net margin of 71.30%. analysts anticipate that CTI BioPharma will post -0.95 earnings per share for the current fiscal year.

CTIC has been the topic of several recent research reports. Cann initiated coverage on CTI BioPharma in a research report on Friday, February 23rd. They issued an “outperform” rating on the stock. Oppenheimer initiated coverage on CTI BioPharma in a research report on Friday, February 23rd. They issued an “outperform” rating and a $5.00 price objective on the stock. JMP Securities initiated coverage on CTI BioPharma in a research report on Wednesday, March 7th. They issued an “outperform” rating and a $8.00 price objective on the stock. Needham & Company LLC initiated coverage on CTI BioPharma in a research report on Monday, March 26th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, Zacks Investment Research lowered CTI BioPharma from a “hold” rating to a “sell” rating in a research report on Tuesday, April 17th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $6.42.

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Insider Buying and Selling by Quarter for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.